SABCS 2021
Good data with further questions for future treatment in a neoadjuvant setting
© 2021 high5md GmbH.
All rights reserved.
high5oncology.tv | Meeting coverage | SABCS 2021
SABCS 2021
Hope Hugo, MD
Good data with further questions for future treatment...
KEYNOTE-522
SABCS 2021
Alessandra Gennari, MD
Metformin is not an anti-cancer drug
CCtGMA.32 (Metformin)
SABCS 2021
Nadia Harbeck, MD
Critical consideration of the study data is necessary
RXPONDER
SABCS 2021
Michael Untch, MD
Negative results with hope for translational projects
PALLAS
SABCS 2021
Peter A. Fasching, MD
The risk-adapted decision for or against AI has to be...
TEXT, SOFT
SABCS 2021
Karen Gelmon, MD
Metformin shows no efficacy for most cancer patients
CCtG MA.32 (Metformin)
SABCS 2021
Andreas Schneeweiss, MD
Molecular-guided treatment is of value in combination...
BRE12-158
SABCS 2021
Rebecca Dent, MD
Solved and unsolved controversies of early breast...
RXPonder; CCtGMA.32 (Metformin)
SABCS 2021
Nadia Harbeck, MD
Hypothesis-generating study in the HER2-enriched...
KEYRICHED-1
Hope Hugo, MD
SABCS 2021
Good data with further questions for future treatment in a neoadjuvant setting
Peter A. Fasching, MD
SABCS 2021
The risk-adapted decision for or against AI has to be redefined
Andreas Schneeweiss, MD
SABCS 2021
Molecular-guided treatment is of value in combination with other therapeutics
Rebecca Dent, MD
SABCS 2021
Solved and unsolved controversies of early breast cancer
Nadia Harbeck, MD
SABCS 2021
Hypothesis-generating study in the HER2-enriched subtype
SABCS 2021
Peter A. Fasching, MD
Muss die risiko-adaptierte Entscheidungsfindung bei AI...
TEXT, SOFT
SABCS 2021
Alessandra Gennari, MD
"Signatures Genomiche " nel carcinoma duttale in situ
Breast Pre-Cancer Atlas
SABCS 2021
Andreas Schneeweiss, MD
Genomisch gesteuererte Therapie sinnvoll in Kombi mit...
Bre12-158
SABCS 2021
Nadia Harbeck, MD
Hypothesen-generierende Studie beim HER2-enriched...
KEYRICHED-1
SABCS 2021
Michael Untch, MD
Negative Ergebnisse, aber Hoffnung für translationale...
PALLAS
SABCS 2021
Alessandra Gennari, MD
La metformina non può essere considerata un farmaco...
CCtGMA.32 (Metformin)
Peter A. Fasching, MD
SABCS 2021
Muss die risiko-adaptierte Entscheidungsfindung bei AI überdacht werden?
Alessandra Gennari, MD
SABCS 2021
"Signatures Genomiche " nel carcinoma duttale in situ
Andreas Schneeweiss, MD
SABCS 2021
Genomisch gesteuererte Therapie sinnvoll in Kombi mit weiteren Therapeutika
Nadia Harbeck, MD
SABCS 2021
Hypothesen-generierende Studie beim HER2-enriched Subtyp
Michael Untch, MD
SABCS 2021
Negative Ergebnisse, aber Hoffnung für translationale Projekte
Alessandra Gennari, MD
SABCS 2021
La metformina non può essere considerata un farmaco antitumorale
SABCS 2021
N. Harbeck, K. Gelmon, S. Tolaney, H. Rugo, M. Untch, A. Schneeweiss
RxPONDER: Benefit only for pre-menopausal patients?...
RxPONDER
SABCS 2021
S. Tolaney, K. Gelmon, N. Harbeck, H. Rugo, A. Schneeweiss, M. Untch
cTRAK TN: ctDNA monitoring not yet ready for primetime....
cTRAK TN
SABCS 2021
H. Rugo, K. Gelmon, S. Tolaney, N. Harbeck, A. Schneeweiss, M. Untch
KEYNOTE-522 confirms ICI benefit in the neoadjuvant...
Keynote-522; OlympiA
N. Harbeck, K. Gelmon, S. Tolaney, H. Rugo, M. Untch, A. Schneeweiss
SABCS 2021
RxPONDER: Benefit only for pre-menopausal patients? OFS/AI > CT? OFS leading to OS benefit?
S. Tolaney, K. Gelmon, N. Harbeck, H. Rugo, A. Schneeweiss, M. Untch
SABCS 2021
cTRAK TN: ctDNA monitoring not yet ready for primetime. Lots of questions, very few answers!
H. Rugo, K. Gelmon, S. Tolaney, N. Harbeck, A. Schneeweiss, M. Untch
SABCS 2021
KEYNOTE-522 confirms ICI benefit in the neoadjuvant setting; what about toxicity?
SABCS 2021
G. Curigliano, A. Schneeweiss, R. Dent, P. A. Fasching, D. Lüftner
HER2+ EBC: Chemotherapy free regimens? Extended...
Destiny-Breast 03; DAISY; SUMMIT
SABCS 2021
R. Dent, A. Schneeweiss, G. Curigliano, P. A. Fasching, D. Lüftner
TNBC EBC: What is the new neoadjuvant standard...
Keynote-522
SABCS 2021
A. Schneeweiss, R. Dent, G. Curigliano, P. A. Fasching, D. Lüftner
MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of...
SABCS 2021
P. A. Fasching, D. Lüftner, R. Dent, G. Curigliano, A. Schneeweiss
HR+ EBC: What about PALLAS/PENELOPE-B? What is the...
PALLAS; PENELOPE-B
G. Curigliano, A. Schneeweiss, R. Dent, P. A. Fasching, D. Lüftner
SABCS 2021
HER2+ EBC: Chemotherapy free regimens? Extended adjuvant therapy? T-Dxd? Duuration of trastuzumab? What about HER2 low?
R. Dent, A. Schneeweiss, G. Curigliano, P. A. Fasching, D. Lüftner
SABCS 2021
TNBC EBC: What is the new neoadjuvant standard treatment? The role of TILS, TMB, further predictive markers for ICI (gene expression signatures, CD8 infiltartion pattern, intrinsic subtypes, ctDNA) and PARP (HRD, sBRCA+, gPALB2+)
A. Schneeweiss, R. Dent, G. Curigliano, P. A. Fasching, D. Lüftner
SABCS 2021
MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of relapse or stratification of post-neoadjuvant treatment, new trials in premenopausal patients, NGS in early disease
P. A. Fasching, D. Lüftner, R. Dent, G. Curigliano, A. Schneeweiss
SABCS 2021
HR+ EBC: What about PALLAS/PENELOPE-B? What is the difference to monarchE (Follow Up, Duraction, Administration, the drug itself)? PARPi vs. cdk4/6i?
SABCS 2021
Elzbieta Senkus-Konefka, MD
Samuraciclib - new targeted therapy for luminal breast...
Samuraciclib Phase I
SABCS 2021
Diana Lüftner, MD
IO + IO without resounding success in the mBC setting
Nimbus
SABCS 2021
Elzbieta Senkus-Konefka, MD
T-Dxd is also active in patients with brain metastasis
Destiny-Breast03
SABCS 2021
Peter A. Fasching, MD
TDXd is very efficient in patients with brain...
DESTINY Breast-03
SABCS 2021
Peter A. Fasching, MD
Pooled analyses shows OS benefit for most subgroups
MONALEESA 2, 3, 7
SABCS 2021
Peter A. Fasching, MD
Patients with BRCA2 don't show PFS benefit with CDK4/6i
MSK IMPACT
SABCS 2021
Peter A. Fasching, MD
Pioneering study of personalized medicine in advanced...
SAFIR02-Breast
SABCS 2021
Carmen Criscitiello, MD
Amazing period for patients with refractory metastatic...
SABCS 2021
Giuseppe Curigliano, MD
Very good news for endocrine resistant metastatic...
EMERALD
SABCS 2021
Karen Gelmon, MD
3 updates - 3 new standards of care
Keynote-522 Keynote-355 Destiny-Breast03
SABCS 2021
Javier Cortes, MD
Final results of the CPS score subgroup analyses show...
Keynote-355
SABCS 2021
Rebecca Dent, MD
Exciting novel therapies for metastatic TNBC
Keynote-355; Tropion-PanTumor01
SABCS 2021
Véronique Diéras, MD
Robust benefit of pembroluzimab in addition to...
KeyNOTE-522
ASH 2021
Carmen Criscitiello, MD
Imaging with mass cytometry can provide predictive...
NeoTRIPaPDL1
SABCS 2021
Volkmar Müller, MD
TROP2 - new target for improved chemotherapy
TROPION-PanTumor01; ASCENT
SABCS 2021
Andreas Schneeweiss, MD
Precision oncology is beneficial in certain mBC...
SAFIR02-Breast
SABCS 2021
Hope Rugo, MD
Which patients will benefit from Pembro in metastatic...
KEYNOT-355
SABCS 2021
Andreas Schneeweiss, MD
Oral SERDs are efficient, but show high progression...
EMERALD
SABCS 2021
Véronique Diéras, MD
PFS improvement with fulvestrant in patients with...
Pada-1
SABCS 2021
Véronique Diéras, MD
Reconfirming effect of T-DXd in patients with brain...
Destiny-Breast03; DAISY
Elzbieta Senkus-Konefka, MD
SABCS 2021
Samuraciclib - new targeted therapy for luminal breast cancer?
Sara Tolaney, MD
SABCS 2021
Immuntherapy for high tumor mutation burden in metastatic breast cancer patients
Elzbieta Senkus-Konefka, MD
SABCS 2021
T-Dxd is also active in patients with brain metastasis
Peter A. Fasching, MD
SABCS 2021
TDXd is very efficient in patients with brain metastasis
Peter A. Fasching, MD
SABCS 2021
Pooled analyses shows OS benefit for most subgroups
Peter A. Fasching, MD
SABCS 2021
Patients with BRCA2 don't show PFS benefit with CDK4/6i
Peter A. Fasching, MD
SABCS 2021
Pioneering study of personalized medicine in advanced breast cancer
Javier Cortes, MD
SABCS 2021
My highlights of 2021 in metastatic breast cancer
Carmen Criscitiello, MD
SABCS 2021
Amazing period for patients with refractory metastatic TNBC
Giuseppe Curigliano, MD
SABCS 2021
Very good news for endocrine resistant metastatic patients
Karen Gelmon, MD
SABCS 2021
3 updates - 3 new standards of care
Javier Cortes, MD
SABCS 2021
Final results of the CPS score subgroup analyses show the optimal cutoff for mTNBC
Rebecca Dent, MD
SABCS 2021
Exciting novel therapies for metastatic TNBC
Andreas Schneeweiss, MD
SABCS 2021
Best of the year: systemic therapy
Véronique Diéras, MD
SABCS 2021
Robust benefit of pembroluzimab in addition to chemotherapy
Carmen Criscitiello, MD
ASH 2021
Imaging with mass cytometry can provide predictive information for therapy with immune checkpoint inhibitors
Volkmar Müller, MD
SABCS 2021
TROP2 - new target for improved chemotherapy
Andreas Schneeweiss, MD
SABCS 2021
Precision oncology is beneficial in certain mBC patients
Hope Rugo, MD
SABCS 2021
Which patients will benefit from Pembro in metastatic TNBC?
Andreas Schneeweiss, MD
SABCS 2021
Oral SERDs are efficient, but show high progression rate
Sara Tolaney, MD
SABCS 2021
Activity of T-Dxd across all Her2-expressing breast cancers
Véronique Diéras, MD
SABCS 2021
PFS improvement with fulvestrant in patients with emerging ESR1 mutation
Véronique Diéras, MD
SABCS 2021
Reconfirming effect of T-DXd in patients with brain metastasis
SABCS 2021
Elzbieta Senkus-Konefka, MD
T-Dxd aktywny również w przerzutach do mózgu
Destiny-Breast03
SABCS 2021
Peter A. Fasching, MD
TDXd zeigt große Wirksamkeit bei Hirnmetastasen
Destiny-Breast-03
SABCS 2021
Peter A. Fasching, MD
Werden orale SERDs die Therapie mit Fulvestrant in...
Emerald
SABCS 2021
Peter A. Fasching, MD
Gepoolte Analyse zeigt OS Vorteil für fast alle...
Monaleesa 2, 3, 7
SABCS 2021
Peter A. Fasching, MD
HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil...
MSK Impact
SABCS 2021
Peter A. Fasching, MD
Wegweisende Daten für die personalisierte Medizin beim...
Safir02-Breast
SABCS 2021
Javier Cortes, MD
Resultados finales de los análisis de los subgrupos de...
Keynote-355
SABCS 2021
Carmen Criscitiello, MD
È un grande momento per i pazienti con tumore mammario...
Tropion-PanTumor01
SABCS 2021
Barbara Pistilli, MD
Risultati promettenti nel tumore al seno triplo...
Tropion-PanTumor01
SABCS 2021
Barbara Pistilli, MD
Résultats prometteurs dans le cancer du sein triple...
Tropion-PanTumor01
SABCS 2021
Giuseppe Curigliano, MD
Buone notizie per i tumori mammari endocrino resistenti
Emerald
SABCS 2021
Véronique Diéras, MD
Important benefice de l’ajout du pembrolizumab à la...
Keynote-522
SABCS 2021
Volkmar Müller, MD
Neues Target für optimierte Chemotherapie
Tropion-PanTumor01; Ascent
SABCS 2021
Carmen Criscitiello, MD
L’imaging mass cytometry può aiutare a predire...
NeoTRIPaPDL1
SABCS 2021
Andreas Schneeweiss, MD
Oraler Serd wirkt, aber hohe Rate an primärer Resistenz
Emerald
SABCS 2021
Véronique Diéras, MD
Amélioration de la survie sans progression par le...
Pada-1
SABCS 2021
Volkmar Müller, MD
Checkpoint-Inhibition beim Mammakarzinom
Nimbus; Keynote-355
SABCS 2021
Andreas Schneeweiss, MD
Umstellung bei molekularem Progress verlängert PFS
PADA-1
SABCS 2021
Elzbieta Senkus-Konefka, MD
Samuracyklib – nowe leczenie celowane w rakach...
Samuraciclib Phase I
SABCS 2021
Véronique Diéras, MD
Activité du T-DXd dans les metastases cérébrales
Destiny-Breast03
SABCS 2021
Andreas Schneeweiss, MD
Präzisionsonkologie funktioniert beim mBC
SAFIR02-BREAST
SABCS 2021
Elzbieta Senkus-Konefka, MD
Dato-DXd – nowy obiecujący koniugat przeciwciała i...
Tropion-PanTumor01
Peter A. Fasching, MD
SABCS 2021
Werden orale SERDs die Therapie mit Fulvestrant in Zukunft ablösen?
Peter A. Fasching, MD
SABCS 2021
Gepoolte Analyse zeigt OS Vorteil für fast alle Subgruppe
Peter A. Fasching, MD
SABCS 2021
HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil durch CDK4/6i
Peter A. Fasching, MD
SABCS 2021
Wegweisende Daten für die personalisierte Medizin beim fortgeschrittenen Mammakarzinom
Javier Cortes, MD
SABCS 2021
Mi retrospectiva del cáncer de mama metastático en 2021
Javier Cortes, MD
SABCS 2021
Resultados finales de los análisis de los subgrupos de puntuación CPS demuestran el umbral ideal para pacientes de cáncer de mama triple negativo metastásico.
Carmen Criscitiello, MD
SABCS 2021
È un grande momento per i pazienti con tumore mammario metastatico triplo-negativo
Barbara Pistilli, MD
SABCS 2021
Risultati promettenti nel tumore al seno triplo negativo
Barbara Pistilli, MD
SABCS 2021
Résultats prometteurs dans le cancer du sein triple négatif
Giuseppe Curigliano, MD
SABCS 2021
Buone notizie per i tumori mammari endocrino resistenti
Andreas Schneeweiss, MD
SABCS 2021
Best of the Year: Systemtherapie
Véronique Diéras, MD
SABCS 2021
Important benefice de l’ajout du pembrolizumab à la chimiothérapie
Volkmar Müller, MD
SABCS 2021
Neues Target für optimierte Chemotherapie
Carmen Criscitiello, MD
SABCS 2021
L’imaging mass cytometry può aiutare a predire l’efficacia dell’immunoterapia
Andreas Schneeweiss, MD
SABCS 2021
Oraler Serd wirkt, aber hohe Rate an primärer Resistenz
Véronique Diéras, MD
SABCS 2021
Amélioration de la survie sans progression par le switch fulvestrant en cas d’apparition mutation ESR1 sous inhibiteurs aromatase
Volkmar Müller, MD
SABCS 2021
Checkpoint-Inhibition beim Mammakarzinom
Andreas Schneeweiss, MD
SABCS 2021
Umstellung bei molekularem Progress verlängert PFS
Elzbieta Senkus-Konefka, MD
SABCS 2021
Samuracyklib – nowe leczenie celowane w rakach luminalnych?
Véronique Diéras, MD
SABCS 2021
Activité du T-DXd dans les metastases cérébrales
Elzbieta Senkus-Konefka, MD
SABCS 2021
Dato-DXd – nowy obiecujący koniugat przeciwciała i cytostatyku
SABCS 2021
J. Cortes, D. Lüftner, C. Criscitiello, V. Dieras, F. Cardos, V. Müller
MBC HER2+: How can we manage the metastatic disease and...
SABCS 2021
V. Dieras, D. Lüftner, C. Criscitiello, F. Cardoso, J. Cortes, V. Müller
MBC TNBC: Molecular tumor characteristics define the...
SABCS 2021
C. Criscitiello, V. Müller, V. Dieras, J. Cortes, F. Cardoso, D. Lüftner
MBC HR+: What is the best option after a CDK4/6i...
SABCS 2021
Cardoso, V. Müller, C. Criscitiello, V. Dieras, J. Cortes, D. Lüftner
Integrating patients perspectives in metastatic breast...
J. Cortes, D. Lüftner, C. Criscitiello, V. Dieras, F. Cardos, V. Müller
SABCS 2021
MBC HER2+: How can we manage the metastatic disease and how can we improve therapy by de-escalating treatment in the metastatic setting?
V. Dieras, D. Lüftner, C. Criscitiello, F. Cardoso, J. Cortes, V. Müller
SABCS 2021
MBC TNBC: Molecular tumor characteristics define the efficacy of new treatments - how do we implement new treatments in clinical practice?
C. Criscitiello, V. Müller, V. Dieras, J. Cortes, F. Cardoso, D. Lüftner
SABCS 2021
MBC HR+: What is the best option after a CDK4/6i therapy?
Cardoso, V. Müller, C. Criscitiello, V. Dieras, J. Cortes, D. Lüftner
SABCS 2021
Integrating patients perspectives in metastatic breast cancer
SABCS 2021
M. Untch, V. Müller, B. Pistilli, A. Gennari, E. Senkus-Konefka
Are SERDs a future therapy for endocrine resistant...
EMERALD
SABCS 2021
V. Müller, A. Gennari, B. Pistilli, E. Senkus-Konefka, M. Untch
Treatment options for patients with metastatic TNBC
Keynote-355
SABCS 2021
M. Untch, E. Senkus-Konefka, A. Gennari, B. Pistilli, V. Müller
Therapy of brain metastasis – can T-DXd be the new SoC?
Destiny-Breast03
SABCS 2021
M. Untch, B. Pistilli, E. Senkus-Konefka, A. Gennari, V. Müller
New ADCs on the horizon for TNBC patients
TROPION-Tumor01
SABCS 2021
V. Müller, A. Gennari, B. Pistilli, E. Senkus-Konefka, M. Untch
Targeting rare mutations in breast cancer - is this the...
SUMMIT
M. Untch, V. Müller, B. Pistilli, A. Gennari, E. Senkus-Konefka
SABCS 2021
Are SERDs a future therapy for endocrine resistant metastatic patients?!
V. Müller, A. Gennari, B. Pistilli, E. Senkus-Konefka, M. Untch
SABCS 2021
Treatment options for patients with metastatic TNBC
M. Untch, E. Senkus-Konefka, A. Gennari, B. Pistilli, V. Müller
SABCS 2021
Therapy of brain metastasis – can T-DXd be the new SoC?
M. Untch, B. Pistilli, E. Senkus-Konefka, A. Gennari, V. Müller
SABCS 2021
New ADCs on the horizon for TNBC patients
V. Müller, A. Gennari, B. Pistilli, E. Senkus-Konefka, M. Untch
SABCS 2021
Targeting rare mutations in breast cancer - is this the way to go?
Do you need a login? team@onkowissen.de
Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Die Fortbildungseinheiten verteilen sich auf folgende Fortbildungsmodule:
Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Die Fortbildungseinheiten verteilen sich auf folgende Fortbildungsmodule: